Abstract
Integrins consists of 24 species with diverse tissue-expression profiles and distinct biological functions. The β subunit of integrin interacts with the FERM-folded head domain of talin through an N-P-x-Y/F motif, triggering integrin activation. Although this motif is conserved across most integrin-β subunits, the detailed molecular mechanisms governing the specific recognition of different integrin species by talin remains unclear. We determined the crystal structure of talin head in complex with the β2-integrin tail. The structure reveals a two-mode configuration featuring a “rocking” motion of the talin head FERM domain when compared with the β3-bound talin head, leading to distinct inter-subdomain interactions and binding affinities. Moreover, stabilizing of the C-terminal α-helix of talin head leads to enhanced affinity to integrin and its activation, suggesting a seesaw model of talin that orchestrates its function in mediating integrin activation in a species-specific manner.
Significance statement Talin exhibits significantly lower affinity with lymphocyte-rich β2 integrins compared with β3 integrins. Our results unveil the configurational preferences of the talin head when engaged β2 and β3 integrins. We introduce a seesaw model wherein the talin head adapts specific binding modes in response to the integrin species. The two configurations differ in inter-subdomain interactions, revealing distinct cavities in each binding mode. These cavities provide novel targets for small molecules that may modulate the structural dynamics of talin and regulate its function in mediating integrin activation. Thus, our findings present exciting opportunities of the development of species-specific therapeutic agents targeting integrin activity more precisely.
Introduction
Integrins are a family of heterodimeric adhesion receptors that play a crucial role in cell adhesion and signaling. Human possesses 24 integrin species, formed by eighteen types of α-subunits and eight types of β-subunits1. These receptors are expressed in a tissue-specific manner and serve distinct biological functions upon activation and clustering of integrin1,2. This process is facilitated by talin and its cofactor, kindlin, through interacting with the cytoplasmic segment of integrin β-subunit3. Activated integrins serve functions essential for cell adhesion, migration, and organ development2,4. Integrin activity is further orchestrated, in a species-specific manner, by posttranslational modification and isoform diversity of the activators5–7, as well as other intracellular regulators such as migfilin, filamin, and paxillin8–10. Considerable efforts have been dedicated to exploring the molecular mechanisms underlying how various species of integrins are regulated and coordinated to precisely serve their specific functions1,2,11–13. Thus, the insights into the species-specific activation of integrin are of great significance for developing therapeutic agents that target integrin with greater precision.
All integrin β subunits except β4 and β8 integrins possess a highly conserved talin-binding site with an N-P-x-Y motif and a loosely conserved kindlin-binding site with the same motif (Fig. 1A). While talin is better known for its function of activating integrins via the “inside-out” pathway, it also connects integrins to cytoskeletal proteins such F-actin and vinculin, promoting integrin outside-in signaling that regulates focal adhesion assembly, cell differentiation, proliferation, and survival14. Integrins position this motif and preceding residues in an integrin-binding groove in the talin head domain (THD) to achieve strong affinity15–17. Among all β-subunits, β1, β2, and β3 integrins have been extensively studied due to their diverse functions across various cell types and their significant roles in disease pathologies. β1 is expressed ubiquitously and engages in various functions when partnering with different α-subunit partners. β2 integrin is exclusively expressed on leukocytes, playing crucial roles in regulating immune responses18. Specifically, αLβ2 (lymphocyte function-associated antigen-1, or LFA-1) is essential for lymphocyte trafficking, adhesion to endothelial cells, and formation of immunological synapses with antigen-presenting cells; αMβ2 (macrophage-1 antigen or Mac-1) mediates macrophage adhesion during inflammation19,20. β3 is predominantly found in platelets and endothelial cells. Integrin αIIbβ3 is a platelet-specific integrin curial for platelet aggregation and adhesion to ligands around vascular injury, thus facilitating thrombus formation and hemostasis 4,21, whereas integrin αvβ3 is pivotal in diverse processes including angiogenesis, bone resorption, and neovascularization22. However, antagonist inhibitors of integrin αvβ3 exhibits high toxicity and poor efficacy, likely due to the unwanted agonism, ligand-free signaling, and impaired functions in inducing apoptosis and angiogenesis23.
Most integrin β subunits possess a cytoplasmic tail containing one talin-binding site and one kindlin-binding site, each harboring an N-P-x-Y/F motif. Crystal structure of talin head in complex with integrin β3 reveals a classic FERM-domain conformation24. A C-terminal poly-lysine motif, conserved in all FERM-domain proteins, stabilizes the FERM domain by mediating inter-subdomain interactions and secures a strong association with the cytoplasmic segment of integrin β324. Moreover, the structure of integrin β1 in complex with a truncated talin head containing the F2-F3 subdomains in complex with integrin β1 reveals a similar integrin-binding groove in the F3 subdomain16. while the isolated F2-F3 subdomains exhibit significantly higher binding affinity with integrin than the full size talin head domain, F2-F3 possesses limited activity in mediating integrin activation15,16. This underscores the crucial role of the structural integrity of talin head16,24. Interestingly, despite the conservation of the talin-binding motif in integrin-β, the structural basis for their widely varying affinities with talin remain elusive. It is also unclear how the FERM-folded talin head distinguishes conserved talin-binding motif in various integrin species to precisely orchestrate the association and signaling activity for diverse integrin functions.
To investigate the molecular basis underlying the activation of various integrin species by talin, we determined the crystal structure of talin head in complex with a peptide derived from the cytoplasmic tail of integrin β2. The structure unveils a similar FERM-domain conformation of talin head with the β2 peptide bound to the talin-binding groove with distinct side chain interactions. Moreover, in contrast to the β3-bound talin head, β2-bound talin head undergoes a significant “rocking” motion, reminiscent of the domain dynamics described in the “seesaw” model15. Structural and affinity measurement indicate that talin head in the β2-bound configuration binds to integrin with a lower affinity than in the β3-bound configuration. Notably, while keeping the interacting residues between talin and integrin intact, mutations restraining the talin head from the β2-bound configuration enhance talin:β2 association. Structural studies indicates that the mutant binds to β2 in the same configuration seen in the β3-bound talin. These observations lead to a hypothesis that stability of the C-terminal α-helix (C-α) in talin head contributes to its enhanced association with integrin. To explore this further, we engineered mutations in talin to stabilize the C-α helix. Talin bearing the mutations exhibits stronger association with integrin and enhanced activity in inducing integrin activation. Thus, the two configurations of the talin head domain exhibit distinct activities in mediating integrin activation, representing different preferences for recognizing β2 and β3 integrins. Our results, for the first time, offer a structural rationale for species-specific integrin activation by talin, providing crucial insight for developing targeted therapies towards various integrin species with greater specificity.
Results
Crystal structure of talin head in complex with β2 reveals a FERM conformation
Integrins engage with various cellular adapter proteins during activation and signaling. The majority of the integrin species possess both talin-binding and kindlin-binding sites within their cytoplasmic tail of the β subunit. Sequence alignment of this segment across various integrin β subunits reveals that both talin- and kindlin-binding sites harbor an NpxY/F motif, commonly found in transmembrane receptors to facilitate signaling transduction through protein-protein interactions. Previous structural studies of β1 and β3 integrins have demonstrated that the talin:integrin-β association is mainly mediated by an 11-residue region centered around an NPxY/F motif. Interestingly, the corresponding region in β2 integrin is rather distinct, with a phenylalanine residue replacing the tyrosine residue in the NPxY/F motif, and one fewer residue compared with β1 and β3 (Fig. 1A). To elucidate the binding specificity of the β2 region and talin head, we generated a fusion protein comprising the talin-binding NPxY/F region from β2 and a full-length talin head lacking the F1-loop, and determined the crystal structures at 1.9 Å (Table 1).
The structure reveals two β2-THD molecules in an asymmetric unit. The two molecules are virtually identical with an overall root-mean-square deviation (RMSD) of 0.06-Å. The talin head domain folds into a FERM conformation, with the integrin-binding F3 subdomain positioning on top of the F1 and F2 subdomains, similar to that of the β3-bound talin head domain (REF). As expected, the fused β2 region is positioned in the β5:C-α groove of a neighboring THD molecule (Fig. 1B). All ten residues of the β2 region are well resolved in the electron density (Fig. 1C). The interaction of the β2 and talin is largely attributed to hydrophobic interactions involving the Pro752, Leu753, and Phe754 residues of the NPxY/F motif with talin-F3 residues in β5 (Lys357), β6-β7 loop (Tyr373) and C-α (Ile396 and Leu400). Additionally, Van-der-Waals and ionic interactions are observed via Arg358, Trp359, Asp372, and backbone of β4-β5 loop from the F3 subdomain (Fig. 1D). The number of residues in β2 between the NPxY/F motif and the juxtamembrane (JM) is one fewer than in other β subunits such as β1 and β3 (Fig. 1A). To evaluate the structural impact of this shortened connection, we analyzed the bound β2 with a β1-D structure that contains the JM region (PDB 3g9w). The structural comparison reveals that while the NPxY/F motifs of β2 and β1-D overlap, the three residues (Asn748, Asn749, and Asp750) preceding the motif in β2 extend to align Asn748 and Asn749 with Asp776 and Thr777 of β1-D. Consequently, the backbone stretching of the shortened connection residues would allow proper interaction of the JM region of β2 with talin (Fig. 1E).
Subdomain tweaking in the talin head FERM domain leads to weakened integrin:talin interaction
Integrin species often exhibit tissue-specific expression patterns and vary in their affinity for talin and other adaptor proteins. We investigated the affinities of β2 integrin with talin using a fluorescence polarization (FP) assay with a FITC-labeled peptide representing both the JM and the NPxY/F regions, along with a purified talin head protein, THD405d (residues 1-405, lacking F1-loop). The β2 peptide exhibits a moderate affinity of 31.9 μM, which is significantly lower than the affinity of the β3 peptide, which was measured at 4.4 μM (Fig. 2A). The sequence variations between the β2 and β3 subunits undoubtedly lead to he observed differences in affinity. Additionally, we investigated how talin adapts to these differences in the β subunit, exploring its capacity to recognize various integrin species to ensure proper function.
Despite the overall similarity of the THD in the β2-bound form and the β3-bound form, the orientation of the subdomains changes noticeably. Superposition of the integrin-binding F3 subdomains of β2-bound THD and β3-bound THD reveals a significant movement in the F1 and F2 subdomains (Fig. 2B). In the β2-bound THD, the F1 subdomain shifts away for F3, creating in a cavity between the F1 and F3 subdomains, while in the β3-bound THD, the two subdomains are in close contact (Fig. 2C). Additionally, the F2 subdomain moves closer to F3 when bound to β2, leading to several new side chain interactions, including Lys306:Glu350, Thr307:Phe312, Glu269/Tyr270:Lys345 at the extended F2-F3 interface (Fig. 2D).
The tweaking of the THD subdomains induces in a shift in the C-α of the F3 subdomain towards the β5 strand, leading to a notable reduction in the size of C-α:β6 groove. Specifically, the distance from the Cβ atom of Ile399 in C-α to Thr354 Cβ in the β4-β5 loop reduces from 9.6-Å to 7.9-Å, resulting in a 5.7° narrowing of the C-α:β6 groove. This change hinders the interaction with the Leucine residue in the NPxY/F motif (where x=Leu in β2 and β3 integrins). In the β3:THD structure, Leu746 of β3 forms a robust hydrophobic cluster with Ile397, Ile399, and Leu400 of THD, whereas in the β2:THD structure, the corresponding Leu753 for β2 is unable to penetrate the C-α:β5 groove deeply enough to engage the hydrophobic sides chains of Ile396 and Ile399, thus retaining only the interaction with Leu400 side chain (Fig. 2E). Talin residues interacting with Asn751, Pro752, and Phe754 of the NPxY/F motif in β2 remain unchanged as those interacting with the corresponding sites in β3. These findings suggest that the C-α shift induced by the subdomain tweaking in THD is the primary cause of the weakened affinity with β2. It appears that FERM-folded THD may accommodates different integrin species through subdomain tweaking. These structural adjustments illustrate how talin’s flexibility enables it to recognize and interact integrins in a species-specific manner, thereby contributing to proper cellular functions.
Mutations at the F2-F3 interface modify the talin:integrin binding mode and integrin activity
We refer to the configuration of β3-bound THD as “Mode A” and the configuration of β2-bound THD as “Mode B” (Fig. 3A). In the “Mode A” configuration, the F3 subdomain tilts to the F1 subdomain, allowing the F1 subdomain to engage and stabilize the C-α helix. Specifically, Ile398 in C-α is sandwiched by Phe197 and Tyr199 via hydrophobic interaction, and Lys401 also forms a salt bridge interaction with Asp125 in the F1 subdomain. These interactions are disrupted in the “Mode B” configuration, as the F3 subdomain shifts towards the F2 subdomain. This shift results in an extensive F2-F3 interface, and the C-α helix retracts from the F1 subdomain, narrowing the integrin binding groove in F3. The tweaking of the subdomains between these two modes is indicated by an RMSD of 4.42 Å.
To assess the impact of the F2-F3 interaction on THD’s configuration, its association with integrin, and role in mediating integrin activation, we introduced mutations in THD, aiming to disrupt the F2-F3 interface. Particularly, a K306Q mutation is introduced to disrupt the Lys306:Glu350 salt bridge and a K306Q/E269A/Y270A (QAA) triple mutation is introduced to disrupt both Lys306:Glu350 and Glu269/Tyr270:Lys345 interactions. We determined the crystal structures of β2:THD(K306Q) and β2:THD(QAA) at 1.97-Å and 2.77-Å, respectively (Fig. 3B). The structure of THD:β2(K306Q) reveals a “Mode B” configuration of THD, nearly identical to that of the THD:β2, with an overall RMSD of 0.17 Å. This comparison suggests that the single mutation is insufficient to disrupt the F2-F3 interface when bound to β2 integrin. Strikingly, the structure of β2:THD(QAA) reveals a THD configuration of “Mode A”, similar to that of THD:β3, with an overall RMSD of 0.69 Å, but completely different from the THD:β2 (RMSD=4.13Å). As both Lys306:Glu350 and Glu269/Tyr270:Lys345 interactions are disrupted, the F2-F3 interface is opened as expected. We then compared the binding of β2 with the THD mutations using the FP assay. Although the affinity of β2 with each THD mutation could not be precisely measured due to limitations in both low affinity and protein solubility, the FP signal notably increases for the THD(QAA) mutation, whereas the FP signal change for THD(K306Q) is negligible (Fig. 3C). These findings indicate that the “Mode A” configuration affords a stronger association with the integrin β subunit than the “Mode B” configuration. We also examined the binding affinities of THD mutations with the integrin β3 peptide. Wild type THD, THD(K306Q) and THD(QAA) exhibit similar affinities, supporting the notion that these mutations would not affect the “Mode A” configuration (Fig. 3D). Furthermore, we assessed the impact of the mutations in talin’s function in mediating integrin activation by a fluorescence activated cell sorting (FACS) assay. CHO (Chinese Hamster Ovary) cells expressing αIIbβ3 integrin were co-transfected with GFP-labeled THD and Kindlin-2, then examined for integrin activity in response to THD expression. Interestingly, although the THD(K306Q) mutation induces integrin activation to a similar level as the wild type THD, THD(QAA) induces integrin activation to a much higher level (Fig. 3E, Fig. S1). Thus, the K306Q/E269A/Y270A triple mutation disrupts the F2-F3 interface, facilitating the “Mode A” configuration of THD. This change enhances the β2 affinity as the enlarged C-α:β5 groove is able to accommodate the Leucine residue in the NPLF motif of β2 to reinstate a hydrophobic cluster. Moreover, although disruption of the F2-F3 interface does not affect the β3-bound THD configuration (Mode A) and the affinity of β3 with THD, it restrains the dynamics of the FERM domain to avoid the “Mode B” configuration and favor the “Mode A” configuration. These findings suggest that the “Mode A” configuration in which the C-α helix is stabilized by F1, represents a state of talin with both high affinity and high activity. Therefore, the equilibrium shift from “Mode B” to “Mode A” of THD may lead to increased integrin activity without altering the apparent affinity with integrin.
Stabilization of talin head C-α enhances integrin association and talin-induced integrin activation
To further investigate the role of C-α in integrin association, we proposed that the stability of C-α contributes to a stronger association with integrin. To test this hypothesis, we introduced mutations with the goal of stabilizing the C-α helix. We identified residue Asp397 in C-α, whose side chain remains isolated from the F1 subdomain and other neighboring side chains in either “Mode A” or “Mode B” configurations. We mutated Asp397 to a positively charged side chain to promote intra-helix interaction with other residues within C-α or inter-subdomain interactions with residues from F1. If successful, these additional interactions would enhance the stability of the C-α helix. To validate the expected additional interaction, we determined the crystal structure of β3:THD(D397R). The structure reveals a “Mode A” THD configuration with an RMSD of 0.39 Å when compared with the wild-type THD when bound to β3 (PDB code: 6vgu) (Fig. 4A). Remarkably, the mutated residue Arg397 forms an intra-helix hydrogen bond with Gln390, forming a side-chain “staple” that stabilizes the C-α helix (Fig. 4A).
We then assessed the association of the mutant THD with integrins. Both THD-D397R or THD-D397K demonstrated improved affinities for β3 integrin. FP assay reveals that THD-D397R enhances its association with β3 integrin by two-fold compared to the wild-type THD, supporting the hypothesis that stabilizing the C-α helix enhances the interaction between talin and integrins (Fig. 4B). In addition, when co-expressed with Kindlin-2 in CHO cells, the THD-D397R mutant induces higher activity of the integrin αIIbβ3 compared to co-expression with wild-type THD (Fig. 4C, Fig. S1). Similarly, vitro pull-down assays showed that THD-D397R also possesses a significantly higher affinity with β2 integrin, further supporting the hypothesis that stabilizing the C-α helix enhances talin:integrin interaction. The result also confirmed the enhanced association with the F2-F3 interface mutation THD(QAA) (Fig. 4D). A truncated talin head domain (talin-400) has been shown to adopt a linear configuration with minimal interaction with integrin and poor activity in activating integrin. We investigated the impact of the mutation on talin-400. Both D397K and D397R mutants exhibit enhanced association with β3 integrin (Fig. S2A). However, the mutants are unlikely to rearrange the subdomains to restore the FERM-folded configuration, which is required to align the F1 loop to engage the integrin α subunit and separate it from the β subunit. Indeed, both mutants failed to effectively induce integrin activation (Fig. S2B, C).
Discussion
Understanding how talin associates with different types of integrins is crucial for unraveling the complex processes of tissue-specific cell adhesion and migration. It also helps identify new targets for therapeutic intervention and development of more specific treatments that reduce side effects caused by cross-reaction with other integrins. β3 integrin, when partnered with different α subunits, plays diverse roles in various cell types, including platelet aggregation (αIIbβ3), bone resorption (αVβ3), and contributes to pathological conditions such as cardiovascular diseases and cancer metastasis. In contrast, β2 integrins are predominantly expressed on leukocytes and platelets and play crucial roles in immune responses by pairing with an exclusive set of integrin α subunits. αLβ2 (LFA-1) is widely expressed on lymphocytes and plays essential roles for lymphocyte migration and T-cell activation. αMβ2 (Mac-1) is abundantly expressed in neutrophils and monocytes and mediates phagocytosis and the inflammatory response 19. αXβ2 (CD11c/CD18) is mainly found on dendritic cells and contributes to antigen presentation and cell adhesion 20. αDβ2 (CD11d/CD18) is strongly expressed on some specific macrophages and may play a role in phagocytosis and atherosclerotic process 25. Together, these beta2 integrins mediate various critical immune processes, including leukocyte trafficking, phagocytosis, and immune cell activation. Our findings reveal different binding modes and affinities of talin when associates with β2 and β3 integrins. In blood cells, β3 is high in platelets and β2 is high in lymphocytes. Platelets respond rapidly to injury by forming blood clots, whereas lymphocytes may require an extended duration to generate effective immune responses. Perhaps the high-affinity talin:β3 binding mode and the low-affinity talin:β2 binding mode reflect the intrinsic mechanisms underlying rapid platelet activation and adhesion, whereas lymphocytes require high specify over the speed for precise immune responses.
While the crystal structure of β2-bound THD reveals a conventional FERM-fold, it exhibits unique conformational characteristics in contrast to the β3-bound THD. With talin’s capacity to recognize integrins with diverse sequences and with post-translation modifications, the structural features of its two binding modes will offer new insight into talin’s specificity across different integrin species. Activated talin translocates to the plasma membrane with the assistance of Rap1, RIAM, or PIPs, allowing it to engage and capture the membrane-anchored integrin β subunits with a “Kon” rate. The “Kon” rate is primarily determined by the abundance of integrins, the surface complementarity between the integrin β and the integrin-binding groove of talin, and the accessibility of the integrin-binding groove. Once talin captures an integrin, the dissociation rate, or Koff, is determined by the stability of the complex. In talin:integrin complex, the flexibility of the C-α helix of talin F3 subdomain is the key factor. In binding mode A, C-α is stabilized by the F1 subdomain, resulting in a lower Koff, and subsequently, a higher affinity for integrin β3. In contrast, in binding mode B, the C-α helix is rather isolated, leading to a higher Koff and a relative lower affinity for integrin β2. In the case of the THD(QAA) mutant, where binding mode A is prioritized, only the affinity of β2, but not β3, is enhanced. This is further supported by the observation that the THD(D397R) mutation, which provides additional stability to the C-α helix, exhibits higher affinity for both β2 and β3 integrins. Nevertheless, integrin activation requires simultaneous association with talin and kindlin. The dynamics of talin, kindlin and integrin-β interaction remains to be elucidated. Recent studies suggest an equilibrium for talin and kindlin to engage integrin-β and form a tertiary complex that is stabilized by a direct interaction of talin-F3. In our study, the presence of kindlin-2 significantly enhances the interaction of integrin β3 with THD(QAA), but not with the wild type THD (Fig. S3). These observations suggest that the mode A configuration, prioritized by the THD(QAA) mutant prioritizes, represents a favorable talin configuration for engaging with kindlin and to act cooperatively, leading to a higher integrin activity.
Our model indicates that talin may interact with various integrin species in different configurations. The difference between the β3-binding mode (mode A) and the β2-binding mode (mode B) focuses mainly on the subdomain interfaces, Mode A features closed F1:F3 and F1:F2 interfaces and an F2-F3 cavity, whereas mode B contains a closed F2:F3 interface and cavities in F1-F2 and F1-F3. The lack of F1:F3 contact in mode B also results in a flexible C-α in F3. These structural distinctions may be utilized to target integrins for therapeutic intervention and to identify pathological biomarkers with greater species specificity. Antagonists of integrins have been developed to inhibit integrin function by blocking the extracellular ligand binding site. Several antagonists that target integrins with high blood cell expression profiles have been approved for medical uses to treat cardiovascular diseases and various types of autoimmune diseases 26. The limitations of these antagonists are reflected in severe adverse effects such as thrombocytopenia, hemorrhage, and the lethal Progressive multifocal leukoencephalopathy (PML) 26,27 caused by unexpected agonism and reactivation of the JC Virus 11,12,28–30. The different binding modes adapted by talin when binding to platelet-rich β3 integrin and leucocyte-rich β2 integrin reveal unique cavities between subdomains, such as the F1-F2 and F1-F3 cavities in the THD:β2 complex and F2-F3 cavities in the THD:β3 (Fig. 4E). These findings thus provide a structural basis for developing small-molecule components that target specific cavities in each configuration mode, thus orchestrating the binding specificity and affinity. The combination of these small-molecules with the antagonists and potentially the peptidomimetics is expected to target integrin species more precisely with reduced adverse effects.
In summary, based on the unique functional properties of TBS, we designed a stapled peptidomimetic compound derived from TBS as a talin inhibitor that targets talin-mediated integrin activation. We developed S-TBS as a “proof-of-concept” experimental agent that validates the unique “double-hit” design strategy. To our knowledge, S-TBS is also the first talin peptidomimetic inhibitor designed based on experimental structures. S-TBS exhibits excellent cell permeability with little cell toxicity, and importantly, it is capable of inhibiting integrin activity by specifically targeting talin intracellularly. We anticipate that this approach of inhibitor design by targeting multiple events in a pathway will not only lead to the discovery of novel anti-integrin drugs but also help identifying new intracellular targets and facilitate the development of related peptidomimetic inhibitors to improve the therapeutic outcomes.
Materials and methods
Plasmid construction
Talin head was subcloned into a modified pET28a vector with a His6-tag. The cytoplasmic tails of different β integrins were subcloned into pGEX-5X-1 vector with a GST-tag. Talin head was subcloned into an EFEP-C3 vector for expression in CHO-A5 cells that express αIIbβ3 integrins stably. For crystallization, a truncated cytoplasmic tail of human integrin β2 (residues 748-757) was fused to the N-terminal of the talin head domain spreading from residue 1 to residue 430 with the deletion of loop (residue 139-168) in the F1 subdomain15. The fusion protein was inserted into a modified pET28a vector, with the His6-tag and linker removed by mutagenesis. Point mutations were generated with a site-directed mutagenesis according to the QuikChange Site-directed mutagenesis manual. All constructs were confirmed by automated DNA-sequencing.
Protein purification
The expression and purification of the His6-tagged proteins and GST-tagged proteins were carried out as described previously. (Gao structure, Zhang PNAS) Briefly, E. coli BL21(DE3) was transformed with modified pET28a-THD constructs or pGEX-5X-1-integrin-β-tail constructs. Bacteria were cultured in LB medium containing 50 µg/ml kanamycin or 80 µg/ml ampicillin in shaking flasks at 200 rpm at 37℃ until the OD600nm reached 0.7. To induce protein expression, 0.2 mM isopropyl-D-1-thiogalactopyranoside (IPTG) was added to the flasks. The flasks were then incubated at 200 rpm, at 16℃ for His6-tagged protein production, or for 3h at 37℃ for GST-tagged protein production. Bacteria were collected by centrifugation and were resuspended in 20 mM Tris, pH 7.5, 500 mM NaCl for His6-tagged proteins, or 20 mM Tris pH 7.5, 100 mM NaCl, 2 mM dithiothreitol (DTT) for GST-tagged proteins. Resuspended cells were homogenized with EmulsiFlex-C3, and the supernatant was collected as the cell extracts. The cell extracts were clarified and applied to HisTrap FF columns (GE LifeSciences) or GSTrap HP columns (GE LifeSciences) for purification using an ÄKTA Purifier system (GE Healthcare).
The expression of untagged proteins (β2-THD, β2-THD(K396Q), β2-THD(QAA), and β3-THD(D397R)) was carried out as described for His6-tagged protein expression. The cell pellet was collected by centrifugation and subsequently resuspended with 20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.0, 80 mM NaCl, 2 mM DTT. The cell extract generated by EmulsiFlex-C3 was loaded onto Hi Prep SP XL 16/10 (Cytiva) for purification using an ÄKTA Purifier system (Cytiva).
Crystallization and structure determination method
Purified untagged proteins were concentrated to 30-45 mg/ml in 20 mM HEPES, pH 7.0, 200 mM NaCl, and 2 mM DTT. Crystallization was performed using the hanging-drop vapor diffusion method at room temperature. The original β2-THD crystal was obtained by seeding microcrystals of β3-THD into the hanging drops in the wells containing a well-solution of 100 mM MES pH 6.5, 100 mM NaCl, 10% PEG400015. Crystals of β2-THD(QAA) and β2-THD(K306Q) were obtained by micro-seeding with crystals of β2-THD. Crystals of β3-THD(D397R) were obtained by micro-seeding using crystals of β3-THD. Crystallization conditions for each protein were further optimized before harvested for data collection. The β2-THD430d crystals were harvested from a well-solution containing 0.1M 2-(N-morpholino) ethanesulfonic acid (MES), pH 6.5, 14% (w/v) polyethylene glycol (PEG) 4000 and 0.12M NaCl. Crystals of β2-THD(K306Q) and Β2-THD(QAA) were harvested from a well solution containing 20% (w/v) polyethylene glycol (PEG) 3350 and 0.25 M Li3Cit. The β3-THD(D397R) crystal for data collection was harvested from a well solution containing 0.1M 2-(N-morpholino) ethanesulfonic acid (MES), pH 6.5, 10% (w/v) polyethylene glycol (PEG) 4000 and 0.1M NaCl. X-ray diffraction data were collected at the Brookhaven National Laboratory NSLS-II AMX and FMX beamlines. The crystal structures were determined by molecular replacement using β3-THD structure (PDB:6VGU) as a model. The structures were refined by COOT and Phenix. The final atomic coordinates and structure factors have been deposited to Protein Data Bank with the following accession numbers: β2-THD (8FSE), β2-THD(QAA) (8T0D), β2-THD(K306Q) (8FTB), and Β3-THD(D397R) (XXXX).
GST pull-down
The pulldown was performed as described previously15. Purified His6-THD proteins and GST-β tail/ GST proteins were mixed in binding buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM DTT) to a final volume of 100 μl at a concentration of 2.1uM and 3.6uM individually. The protein mixture was left on ice for 15 min then incubated with binding buffer-equilibrated glutathione agarose beads (Invitrogen, G2879) on a rotator for 1h at 4 ℃. After removing the supernatant, the beads were washed with binding buffer three times. The beads-binding proteins were eluted with 30ul elution buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM DTT, 20 mM reduced glutathione). The samples were applied to SDS/PAGE and analyzed by Coomassie staining or Western Blotting. Anti-His (Sigma) was used for the detection of His6-tagged THD proteins. Anti-Kindlin-2 (CST) was used for the detection of the kindlin-2 protein. A FluorChem E System (Proteinsimple) with a charge-coupled device (CCD) camera was used to expose the Western blotting membrane.
Fluorescent polarization
The Fluorescent polarization assay was carried out as previously described. (Gao structure). The talin head protein solutions (at a proper series concentration) or buffer (20 mM Tris pH 8.0, 100 mM NaCl, 2 mM DTT) were mixed with 20 nM FITC-β2 (Genemed Synthesis, Inc.) or FAM-β3 (Genemed Synthesis, Inc.) in 20 mM Tris pH 8.0, 100 mM NaCl, 2 mM DTT, 0.5% Tween-20. The mixture was incubated on ice for 3 min then 20 µl was aliquoted to a 384-well plate (Corning, 3573) for measurement with Perkin Elmer Envision Plate Reader. The excitation filter was FITC FP 480nm and emission filter was a pair of FITC FP P-pol 535nm. All the polarization signals were normalized by subtracting the background signal generated by the buffer and fit to a single-site (saturating) binding model using Prism 9.
Integrin activation assays
The CHO-A5 cells that expressed αIIbβ3 integrins were transfected with EGFP-C3-THD constructs and incubated at 37℃ for 36H. The cells were detached with an enzyme-free cell dissociation solution (Sigma, c5914-100ml) and washed with PBS. Then CHO-A5 cells were incubated with PAC-1 antibody (Invitrogen, MA5-28523, 1:50) in Tyrode’s buffer (136.9 mM NaCl, 10 mM HEPES, 5.5 mM Glucose, 11.9 mM NaHCO3, 2.7 mM KCl, 0.5 mM CaCl2, 1.5 mM MgCl2, 0.4 mM, NaH2PO4, pH 7.4) for 30 min at RT, followed by incubation with Alexa 647 goat anti-mouse IgM (Jackson Immuno Research Labs, NC0401238, 1:400) in Tyrode’s buffer for 30min on ice in the dark. After washing, the cells were resuspended with PBS and quantified with a Symphony A5 analyzer (660/20 filter, 640 nm laser) using 30,000 cells per measurement. All the data were processed with FlowJo v9.
Statistics
The crystallographic data were processed and refined with COOT, PHENIX, and REFMAC. The data of fluorescent polarization assays were normalized by subtracting the background signal generated by the buffer only. In integrin activation assay, the background signal of GFP-transfected cells was subtracted and all the data were normalized to the integrin activity level generated by GFP-THDwt transfection. Data represent the mean of triplicates with error bars representing ±SD. The statistical significances were determined using unpaired two-tailed Student’s T-test.
Author Contributions
T.G. and S.K. performed protein production and the FP assays. T.G. performed protein crystallization, data collection, biochemical experiments, and the cell-based functional experiments. T.G. and J.W. determined the structures and wrote the manuscript. J.W. supervised the project and was the principal manuscript author.
Declaration of Interests
The authors declare no competing financial interests.
Acknowledgments
We thank Dr. Bernhard Wehrle-Haller (University of Geneva) for the discussions. We thank the beamline staff of AMX and FMX at National Synchrotron Light Source-II, Brookhaven National Laboratory, 7B2 at MacCHESS, Cornell University, for technical support. This work was supported by an NIH Grant GM119560 (to J.W.), an ASH bridge grant (to J.W.), a Pennsylvania Department of Health Grant 4100085739 (to J.W.), and ACS RSG-15-167-01-DMC (to J.W.). T.G. was partially supported by the Elizabeth Knight Patterson Postdoctoral Fellowship. S.K. was partially supported by the Jeanne E. and Robert F. Ozols Undergraduate Summer Research Fellowship.